新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » Express Scripts将其合约研究机构业务出售给私人资本公司

Express Scripts将其合约研究机构业务出售给私人资本公司

来源:生物谷 2013-08-21 19:18

2013年8月21日讯 /生物谷BIOON/ --Express Scripts公司的合约研究部门Bracket已经被出售给一家私人资本公司Parthenon Capital Partners。合约双方并未透露具体细节,但毫无疑问,在Parthenon公司的支持下,在全球拥有广泛业务的Bracket将迎来一个新的发展期。

Bracket公司成立已经超过十年,公司于2012年被Express Scripts收购。(生物谷Bioon.com)

详细英文报道:

Bracket, the pharma contracting arm of Express Scripts, is now the property of Parthenon Capital Partners, the latest private equity takeover in a fast-consolidating industry.

Neither party disclosed financial details, but Parthenon will be the new home for a contractor that has worked on 1,100 trials across 47 therapeutic areas, providing eClinical and scientific services across all phases of development. Now, backed by Parthenon and its track record of supporting growth-oriented companies, Bracket can keep expanding its capacity around the globe, President Catherine Spear said.

"As an independent company, Bracket will now have the autonomy, flexibility and resources to pursue our growth strategy and continue to provide best-in-breed technology-enabled solutions for our clients," Spear said in a statement.

Like many in private equity, Parthenon has a close eye on the CRO world, and the company figures the market for Bracket's technology to ensure trial efficiency and data integrity will only grow, Managing Partner David Ament said.

"We have been studying the clinical trials specialty services market for several years and believe Bracket offers a unique and highly compelling set of solutions to the industry," Ament said.

Bracket has been around for more than decade, first as a division of United BioSource, which was bought by Medco Health Solutions in 2010, which was then purchased by Express Scripts in 2012.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库